{
    "clinical_study": {
        "@rank": "42000", 
        "arm_group": [
            {
                "arm_group_label": "enoxaparin", 
                "arm_group_type": "Experimental", 
                "description": "enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days"
            }, 
            {
                "arm_group_label": "rivaroxaban", 
                "arm_group_type": "Experimental", 
                "description": "rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery"
            }, 
            {
                "arm_group_label": "dabigatran", 
                "arm_group_type": "Experimental", 
                "description": "dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine which of the following drugs: enoxaparin,\n      dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR)."
        }, 
        "brief_title": "Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hip Osteoarthritis", 
            "Blood Loss"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Osteoarthritis", 
                "Osteoarthritis, Hip"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  primary, end-stage hip osteoarthritis requiring total hip arthroplasty\n\n        Exclusion Criteria:\n\n          -  inflammatory arthropathies\n\n          -  liver disorders\n\n          -  neoplastic conditions\n\n          -  clotting disorders"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085824", 
            "org_study_id": "CPX-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "enoxaparin", 
                "intervention_name": "Enoxaparin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "rivaroxaban", 
                "intervention_name": "rivaroxaban", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "dabigatran", 
                "intervention_name": "dabigatran", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Otwock", 
                    "country": "Poland", 
                    "state": "Woj. Mazowieckie", 
                    "zip": "05-400"
                }, 
                "name": "Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education"
            }, 
            "investigator": {
                "last_name": "Marcin K Wasko, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.", 
        "overall_contact": {
            "email": "m.wasko@cmkp.edu.pl", 
            "last_name": "Marcin K Wasko, M.D., Ph.D.", 
            "phone": "+48227794031", 
            "phone_ext": "384"
        }, 
        "overall_official": {
            "affiliation": "The Medical Centre of Postgraduate Education, Department of Orthopaedics and Inflammatory Disorders of Locomotor System", 
            "last_name": "Marcin K Wasko, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured for each individual. Measured according to the formula described by Nadler, Hidalgo and Bloch (Prediction of blood volume in normal human adults. Surgery 1962;51:224-32).", 
            "measure": "Total blood loss by the 3rd postoperative day", 
            "safety_issue": "No", 
            "time_frame": "3rd day postoperatively"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085824"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical Centre of Postgraduate Education, Poland", 
            "investigator_full_name": "Marcin Wasko MD PhD", 
            "investigator_title": "Dr Marcin Wasko MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference between haemoglobin on the 3rd postopertive day and day before operation", 
                "measure": "Drop in the haemoglobin value between 3rd day postop and preoperative", 
                "safety_issue": "No", 
                "time_frame": "3rd day postopertively"
            }, 
            {
                "description": "Wound healing disturbances - diagnosis to be made according to the definition of Centers for Disease Control and Prevention (Mangram, Horan, Pearson, Silver and Jarvis. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78)", 
                "measure": "Wound healing disturbances according to the definition of Centers for Disease Control and Prevention", 
                "safety_issue": "No", 
                "time_frame": "3 months postoperatively"
            }
        ], 
        "source": "Medical Centre of Postgraduate Education, Poland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical Centre of Postgraduate Education, Poland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}